LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Reed, Reiss
Languages: English
Types: Doctoral thesis
Subjects: R1
T-cells appear to have multiple conflicting roles in CLL. On the one hand tumour-specific T-cells could be used to deliver effective immunotherapy; on the other hand, certain T-cell populations may enhance CLL survival and disease progression. The aim of this thesis was to address these contradictory aspects and to provide a deeper understanding of the role of T-cells in CLL.\ud Firstly, candidate peptides from the pro-apoptotic protein Bax were used to activate potential CLL specific T-cells from HLA-A2+ patients. A CD8+ T-cell clone (6C5) was isolated and it’s specificity was initially mapped to (Bax161-170; LLSYFGTPT) and(Bax160–170; GLLSYFGTPT). However, 6C5 failed to recognise HLA-A2+ CLL cells in vitro,\ud and failed to recognise highly purified forms of the peptides. Further characterisation, involving mass spectrometry and HPLC, mapped T-cell specificity to a modified peptide (LLSY(3-tBu)FGTPT). A second strand of this project involved detailed phenotypic analysis of T-cells from CLL patients (n=97) in order to investigate the basis for immune dysfunction. This analysis indicated that patients with an inverted CD4:CD8 ratio (CLLIR), displayed a\ud skewing towards a highly differentiated T-cell phenotype, as well as expression of markers associated with replicative senescence (CD57+, CD27-) within CD4+ and CD8+ T-cell compartments. In addition, CD4+ T-cells expressing markers associated with immunosuppression (PD-1+, TIM-3+) were also increased in CLLIR. Importantly, the\ud inversion of the CD4:CD8 ratio was associated with shorter progression-free survival.\ud Furthermore, the frequencies of distinct T-cell populations were also shown to haveprognostic impact in both univariate analysis (CD4+PD-1+, CD4+CD57+, CD8+CD57+ and\ud CD8+CD27-) and multivariate analysis (CD4+CD27-PD-1+LAG-3+ and CD8+CD27- CD57+PD-1+).\ud To further evaluate the differences between CLLIR and CLLNR patients, preliminary transcriptional analysis was performed, focusing on genes associated with T-cell function.\ud By contrast, transcriptional analysis suggested that genes associated with activation rather\ud than suppression were enriched in CLLIR
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Chapter 5 Gene expression analysis of T-cells in CLL............................ 187 5.1 CD4+ T-cell analysis ..................................................................................................... 189 5.2 CD8+ T-cell analysis ..................................................................................................... 193 5.3 Discussion ...................................................................................................................... 196 5.4 Suggested further work ................................................................................................ 204 Jonker, D.J., O'Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.-J., Berry, S.R., et al. 2007. Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine 357(20), pp. 2040-2048.
    • 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373(6513), pp. 444-448.
    • June, C.H. 2007. Adoptive T cell therapy for cancer in the clinic. The Journal of Clinical Investigation 117(6), pp. 1466-1476.
    • Kaech, S.M. and Cui, W. 2012. Transcriptional control of effector and memory CD8+ T cell differentiation. Nature Reviews Immunology 12(11), pp. 749-761.
    • Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. and June, C.H. 2011.
    • T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine 3(95), p. 95ra73.
    • Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, Kaspar, A.A., Okada, S., Kumar, J., Poulain, F.R., Drouvalakis, K.A., Kelekar, A., Hanson, D.A., et al. 2001. A Distinct Pathway of Cell-Mediated Apoptosis Initiated by Granulysin.
    • The Journal of Immunology 167(1), pp. 350-356.
    • Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P.F., et al. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. The Journal of Immunology 154(8), pp. 3961-3968.
    • Keating, M.J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., et al. 2002.
    • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99(10), pp. 3554-3561.
    • Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. 2008. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology 26, pp. 677-704.
    • Kerkar, S.P. and Restifo, N.P. 2012. Cellular constituents of immune escape within the tumor microenvironment. Cancer Research 72(13), pp. 3125-3130.
    • Kershaw, M.H., Westwood, J.A., Slaney, C.Y. and Darcy, P.K. 2014. Clinical application of genetically modified T cells in cancer therapy. Clinical & translational immunology 3(5), p. e16.
    • Khaled, Y.S., Ammori, B.J. and Elkord, E. 2013. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunology and cell biology 91(8), pp. 493-502.
    • Khanna, R. 2004. Predictive algorithms and T cell epitope mapping. The Journal of Immunology 173(5), pp. 2895-author reply 2895-6.
    • 2013. T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile. Cancer Immunology, Immunotherapy 62(1), pp. 51-63.
    • Kim, R., Emi, M. and Tanabe, K. 2007. Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1), pp. 1-14.
    • Kim, R., Emi, M., Tanabe, K. and Arihiro, K. 2006. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Research 66(11), pp.
    • King, J., Waxman, J. and Stauss, H. 2008. Advances in tumour immunotherapy. QJM : monthly journal of the Association of Physicians 101(9), pp. 675-683.
    • Klebanoff, C.A., Acquavella, N., Yu, Z. and Restifo, N.P. 2010. Therapeutic cancer vaccines: are we there yet? Immunological reviews 239(1), pp. 27-44.
    • Klebanoff, C.A., Gattinoni, L. and Restifo, N.P. 2006. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunological reviews 211, pp. 214-224.
    • Klebanoff, C.A., Gattinoni, L. and Restifo, N.P. 2012. Sorting Through Subsets. Journal of Immunotherapy 35(9), pp. 651-660.
    • Knauf, W.U., Lissichkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Lee, H.-W., Park, S.-J., Choi, B.K., Kim, H.H., Nam, K.-O. and Kwon, B.S. 2002. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl1. The Journal of Immunology 169(9), pp. 4882-4888.
    • Lee, J., Su, E.W., Zhu, C., Hainline, S., Phuah, J., Moroco, J.A., Smithgall, T.E., et al. 2011.
    • Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways.
    • Molecular and Cellular Biology 31(19), pp. 3963-3974.
    • Li, F.-J., Zhang, Y., Jin, G.-X., Yao, L. and Wu, D.-Q. 2013. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients. Immunology Letters 150(1-2), pp. 116-122.
    • Li, Z. 2004. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes & Development 18(1), pp. 1-11.
    • Maus, M.V., Grupp, S.A., Porter, D.L. and June, C.H. 2014. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17), pp. 2625-2635.
    • Mayr, C., Bund, D., Schlee, M., Bamberger, M., Kofler, D.M., Hallek, M. and Wendtner, C.-M. 2006. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Experimental Hematology 34(1), pp. 44-53.
    • Mayr, C., Bund, D., Schlee, M., Moosmann, A., Kofler, D.M., Hallek, M. and Wendtner, C.-M. 2005. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 105(4), pp. 1566-1573.
    • 1975. Clinical staging of chronic lymphocytic leukemia. Blood 46(2), pp. 219-234.
    • Rajasagi, M., Shukla, S.A., Fritsch, E.F., Keskin, D.B., DeLuca, D., Carmona, E., Zhang, W., et al. 2014. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124(3), pp. 453-462.
    • 2009. Affinity-based selection of regulatory T cells occurs independent of agonist-mediated induction of Foxp3 expression. The Journal of Immunology 182(3), pp. 1341-1350.
    • Rezk, S.A. and Weiss, L.M. 2007. Epstein-Barr virus-associated lymphoproliferative disorders. Human Pathology 38(9), pp. 1293-1304.
    • Ricci, F., Tedeschi, A., Morra, E. and Montillo, M. 2009. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Therapeutics and clinical risk management 5(1), pp.
    • Richardson, S.J., Matthews, C., Catherwood, M.A., Alexander, H.D., Carey, B.S., Farrugia, J., Gardiner, A., et al. 2006. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
    • Blood 107(9), pp. 3584-3592.
    • Riches, J.C., Davies, J.K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A.G., et al. 2013. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121(9), pp. 1612-1621.
    • Riedl, S.J. and Salvesen, G.S. 2007. The apoptosome: signalling platform of cell death.
    • Nature Reviews Molecular Cell Biology 8(5), pp. 405-413.
    • Riese, R.J., Wolf, P.R., Brömme, D., Natkin, L.R., Villadangos, J.A., Ploegh, H.L. and Chapman, H.A. 1996. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 4(4), pp. 357-366.
    • Rincón, M. and Flavell, R.A. 1994. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. The EMBO Journal 13(18), pp. 4370-4381.
    • Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., Mortarini, R., et al. 2002. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
    • Immunological reviews 188(1), pp. 97-113.
    • Robak, T., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., et al. 2010. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 28(10), pp.
    • Roche, P.A. and Cresswell, P. 1990. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 345(6276), pp. 615-618.
    • Roche, P.A., Marks, M.S. and Cresswell, P.J. 1991. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 354(6352), pp. 392-394.
    • Rock, K.L. and Shen, L. 2005. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunological reviews 207(1), pp. 166-183.
    • Rodig, S.J., Abramson, J.S., Pinkus, G.S., Treon, S.P., Dorfman, D.M., Dong, H.Y., Shipp, M.A., et al. 2006. Heterogeneous CD52 Expression among Hematologic Neoplasms: Saliba, A.-E., Westermann, A.J., Gorski, S.A. and Vogel, J. 2014. Single-cell RNA-seq: advances and future challenges. Nucleic Acids Research 42(14), pp. 8845-8860.
    • Sloan, V.S., Cameron, P., Porter, G., Gammon, M., Amaya, M., Mellins, E. and Zaller, D.M. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375(6534), pp. 802-806.
    • Smith, D.M., Benaroudj, N. and Goldberg, A. 2006. Proteasomes and their associated ATPases: A destructive combination. Journal of Structural Biology 156(1), pp. 72-83.
    • Song, D.G., Ye, Q., Poussin, M., Harms, G.M., Figini, M. and Powell, D.J. 2012. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119(3), pp. 696-706.
    • Speedy, H.E., Di Bernardo, M.C., Sava, G.P., Dyer, M.J.S., Holroyd, A., Wang, Y., Sunter, N.J., et al. 2013. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nature Genetics 46(1), pp. 56-60.
    • Srinivasan, L., Sasaki, Y., Calado, D.P., Zhang, B., Paik, J.H., DePinho, R.A., Kutok, J.L., et al. 2009. PI3 Kinase Signals BCR-Dependent Mature B Cell Survival. Cell 139(3), pp. 573- 586.
    • Stavnezer, J., Guikema, J.E.J. and Schrader, C.E. 2008. Mechanism and regulation of class switch recombination. Annual Review of Immunology 26, pp. 261-292.
    • Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B. and Mach, B. 1994.
    • Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivatior Gene CIITA. Science 265, pp. 106-109.
    • Steinman, R.M. and Idoyaga, J. 2010. Features of the dendritic cell lineage. Immunological reviews 234(1), pp. 5-17.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article